2 active not recruiting, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
Follow Arctic Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV) AT-004, Placebo - Acne Vulgaris on the Face | Phase 2 | Completed | Arctic Therapeutics | 63 | 2026-02-02 | 2026-08-19 |
| Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) NPI-001, Placebo - Alzheimer´s Disease | Phase 2 | Active not recruiting | Arctic Therapeutics | 33 | 2025-10-14 | 2026-08-03 |
| Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) NACA - Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain | Phase 2 | Active not recruiting | Arctic Therapeutics | 15 | 2024-04-03 | 2026-07-21 |
Dementia (2) · Acne Vulgaris (1) · Cerebral Amyloid Angiopathy, Familial (1) · Cerebral Hemorrhage (1) · Cognitive Dysfunction (1) · Intracranial Hemorrhages (1)
caficrestat (1)
Denmark (2) · Iceland (2)
2023 (1), 2025 (1)